EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients

Magali Amiel iD, Alice Ke iD, Steven P Gelone, Hannah M Jones, Wolfgang Wicha iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Magali Amiel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Ltd., Sheffield, UK. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones, Aminophenols, Diterpenes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lefamulin is being evaluated as a treatment for bacterial exacerbations in cystic fibrosis (CF). Ivacaftor is approved for the treatment of patients with CF. Lefamulin is a moderate CYP3A inhibitor and co‐administration with ivacaftor may result in a drug–drug interaction (DDI). A CF population was built based on literature using the Simcyp Simulator. A previously developed and validated physiologically‐based pharmacokinetic (PBPK) model for ivacaftor was used. A PBPK model for lefamulin was developed and verified. Predicted concentrations and pharmacokinetic (PK) parameters for both ivacaftor and lefamulin in healthy subjects and patients with CF were in reasonable agreement with observed data (within 1.4‐fold, majority within 1.25‐fold). The lefamulin model as a CYP3A4 perpetrator was validated using a different Ki value for oral (p.o.) and intravenous (i.v.) routes. The simulated changes in area under the curve of ivacaftor in patients with CF when co‐administered with p.o. and i.v. lefamulin were weak‐to‐moderate. The predicted change in ivacaftor PK when co‐administered with oral lefamulin was less than observed between ivacaftor and fluconazole. These results suggest a low liability for a DDI between lefamulin and ivacaftor in patients with CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesAminophenolsDiterpenesPolycyclic CompoundsThioglycolatesHumansCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3ADrug InteractionsModels, Biological

Substanzen

ivacaftorlefamulinQuinolonesCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3AAminophenolsDiterpenesPolycyclic CompoundsThioglycolates

Autor:innen und Institutionen

  • Certara UK Ltd., Sheffield, UK.
  • Nabriva Therapeutics US, Inc., Fort Washington, Pennsylvania, USA.
  • Nabriva Therapeutics GmbH, Vienna, Austria.

ORCID-Profile: Magali Amiel, Alice Ke, Wolfgang Wicha

Zitieren

APA

Amiel, M., Ke, A., Gelone, S. P., Jones, H. M., & Wicha, W. (2024). Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13103

Vancouver

Amiel M, Ke A, Gelone SP, Jones HM, Wicha W. Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13103

BibTeX
@article{Amiel2024,
  author = {Amiel, Magali and Ke, Alice and Gelone, Steven P and Jones, Hannah M and Wicha, Wolfgang},
  title = {Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13103}
}
Kostenlos starten →